Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Odronextamab→

Odronextamab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1801338-64-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Bispecific monoclonal antibodyCD20×CD3 T-cell-engaging immunotherapy
Mechanism of action
Binds CD20 on B-lineage cells and CD3 on T cells, bringing T cells into close proximity with malignant B cells and promoting T-cell-mediated cytotoxicity against CD20-expressing cells.
Indications / reported uses
  • Investigational treatment studied in adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma; this is not a statement of a universal marketing authorisation.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/odronextamab

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Bispecific monoclonal antibody; CD20×CD3 T-cell-engaging immunotherapy

Mechanism of action

Binds CD20 on B-lineage cells and CD3 on T cells, bringing T cells into close proximity with malignant B cells and promoting T-cell-mediated cytotoxicity against CD20-expressing cells.

General use cases

  • Investigational treatment studied in adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma; this is not a statement of a universal marketing authorisation.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Odronextamab Environmental Risk Assessment (ERA) (the Odronextamab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.